Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

NCT Number	NCT06515262
Lead Sponsor	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Collaborators: Guangzhou Bio-gene Technology Co., Ltd
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	10 participants
Start Date	2024-07-01
Primary Completion	2026-11 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-07-23